Skip to main content
. 2022 Mar 25;22:135. doi: 10.1186/s12876-022-02210-3

Table 6.

Tumor response

Lenvatinib (N, %) Sorafenib (N, %) p-value
CR 2 (4.5%) 3 (3.4%)
PR 6 (13.6%) 1 (1.1%)
SD 26 (59.1%) 38 (43.2%)
PD 10 (22.7%) 44 (50.0%)
Not assessed 0 (0%) 2 (2.3%)
ORR 18.2% 4.5% 0.020
DCR 77.3% 47.7% 0.001

Data are presented as number (%)

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate